AstraZeneca's (LON:AZN) Equal weight Rating Reiterated at Morgan Stanley

Cornelia Mascio
Dicembre 13, 2017

PVG Asset Management Corp's holdings in AstraZeneca were worth $2,370,000 at the end of the most recent quarter.

A number of other brokerages also recently issued reports on AZN. Aperio Group LLC boosted its position in Astrazeneca PLC by 4.4% in the third quarter. Russell Investments Group Ltd. now owns 1,856,140 shares of the company's stock worth $62,883,000 after purchasing an additional 1,235,239 shares during the last quarter. Valeo Financial Advisors LLC bought a new position in shares of Astrazeneca during the 3rd quarter worth approximately $133,000. Janus Henderson Group PLC raised its position in shares of AstraZeneca by 5,754.0% in the 3rd quarter. The institutional investor owned 28,463 shares of the company's stock after selling 1,647 shares during the period. Voya Investment Management LLC raised its holdings in shares of AstraZeneca by 38.2% during the 2nd quarter. 853,736 shares of the company were exchanged, compared to its average volume of 2,130,000. Point72 Asset Management L.P. now owns 1,224,939 shares of the company's stock worth $41,501,000 after acquiring an additional 621,831 shares in the last quarter.

Several equities research analysts recently commented on the company. BMO Capital Markets started coverage on shares of Astrazeneca in a research report on Wednesday, September 6th. Shore Capital restated a hold rating on shares of AstraZeneca in a research report on Tuesday, October 31st. Finally, UBS set a GBX 4,550 ($61.24) target price on AstraZeneca and gave the stock a neutral rating in a research report on Monday, October 9th. Argus reissued a "buy" rating and issued a $35.00 price objective on shares of Astrazeneca in a research report on Friday, September 1st. Barclays restated an overweight rating and set a GBX 5,500 ($74.02) price objective on shares of AstraZeneca in a research note on Monday, August 7th. set a GBX 4,100 ($55.18) price objective on shares of AstraZeneca and gave the company a sell rating in a research note on Tuesday, August 8th. Four investment analysts have rated the stock with a sell rating, seven have issued a hold rating and twelve have assigned a buy rating to the company's stock. The stock has an average rating of "Hold" and an average target price of $35.84. Astrazeneca has a 52-week low of $25.55 and a 52-week high of $35.60. The stock has a market cap of $83,172.78, a PE ratio of 7.84, a PEG ratio of 3.19 and a beta of 0.73. The company has a debt-to-equity ratio of 1.09, a current ratio of 0.94 and a quick ratio of 0.72.

Nicholas Hoffman & Company LLC. reduced its stake in Astrazeneca PLC (NYSE:AZN) by 5.5% during the first quarter, according to its most recent filing with the SEC. The company reported $1.12 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $0.57 by $0.55. The business had revenue of $6.23 billion during the quarter, compared to the consensus estimate of $6 billion. Astrazeneca had a net margin of 15.90% and a return on equity of 34.02%. The business's quarterly revenue was up 9.4% compared to the same quarter previous year. If you are reading this news story on another domain, it was stolen and republished in violation of USA & global trademark & copyright law.

Altre relazioniGrafFiotech

Discuti questo articolo

Segui i nostri GIORNALE